Brought to you by 
Hyperion Therapeutics gets $60mm through its Series C
17 Jul 2009
Executive Summary
Hyperion Therapeutics (developing GI and hepatic drug candidates) has raised $60mm through the closing of its Series C venture round. First-time investors Bay City Capital and Panorama Capital co-led and were joined by returning backers Highland Capital Partners, NEA, and Sofinnova Ventures. The company will use the money to study HPN100 in Phase III trials for chronic urea cycle disorders and Phase II for low-grade hepatic encephalopathy. Representatives from Bay City Capital and Panorama Capital will take seats on Hyperion's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hyperion Therapeutics gets $60mm through its Series C
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice